### Learner Notification

**MED Learning Group**

**Clinical Practice Pearls: Managing Patients with Major Depressive Disorder Showing an Inadequate Response to First-Line Therapies**

**June 29 – October 30, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

Takeda Pharmaceuticals, Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Improve the treatment of patients with MDD showing an inadequate response to first-line therapies.
2. Support shared decision-making and patient-centered, approaches to the management of patients with MDD.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Laura | Aibara | NA |
| Anita H. | Clayton | Daré Bioscience, Janssen, Otsuka, Praxis Precision Medicines, Relmada Therapeutics, Inc.m, Sage Therapeutics: Grant Research, AbbVie, Brii Biosciences, Fabre-Kramer, Janssen Research & Development, Mind Cure Health, MycoMedica Life Sciences, Praxis Precision Medicines, PureTech Health; Reunion Neuroscience, S1 Biopharma, Sage Therapeutics, Takeda/Lundbeck, Vella Bioscience: Scientific/Medical Advisory Board/Consultant, Ballantine Books/Random House, Changes in Sexual Functioning Questionnaire, Guilford Publications: Royalties/Copyright, Stock Shareholder: Euthymics Bioscience, Mediflix, and S1 Biopharma |
| Dan | DaSilva | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Sylvia | Hanna | NA |
| Greg | Mattingly | AbbVie, Alkermes, Axsome, Corium, Intra-Cellular Therapies, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda Pharmaceuticals, Tris Pharma: Speakers Bureau, AbbVie, Alkermes, Axsome Therapeutics, Biogen, Corium, Eisai, Ironshore, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda Pharmaceutcials, Teva: Consultant, AbbVie, Alkermes, Akili, Axsome, Boehringer, Emalex Biosciences, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceutics, Otsuka, Redax, Relmada Therapeutics, Inc.; Roche, Sage Therapeutics, Sirtsei, Sunovion, Supernus, Takeda Pharmaceuticals, Teva: Research |
| Jessica | McMullen | NA |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)